Dr Martin Kaiser’s group aims to design gentler, tailored therapies for patients with multiple myeloma, an immune cell cancer of the bone marrow.
Professor Martin Kaiser is the Chair of Haematology, group leader of the Myeloma Molecular Therapy group, and an Honorary Consultant Haematologist at The Royal Marsden NHS Foundation Trust.
I joined the team in December 2020 and I am involved in the bio-banking of samples from national myeloma clinical trials. I use flow cytometry and a variety of molecular biology techniques to assess molecular profiles and genetic aberrations in patients with multiple myeloma.